![]() |
|
|
Vol. 290, Issue 2, 901-907, August 1999
Lilly Research Laboratories, Eli Lilly and Company, Indianapolis,
Indiana (H.E.S, J.C.H., F.P.B., D.O.C., N.W.D, C.H.M., J.S.W.); and
Novo Nordisk A/S, Health Care Discovery, Måløv, Denmark (A.F.J.,
P.S., L.J., M.J.S., M.D.B.S)
The purpose of our studies was to determine the effects of muscarinic
receptor agonists on conditioned avoidance responding in the
rat. Rats were trained to avoid or escape an electric shock delivered to the feet in a discrete trial procedure. The muscarinic receptor agonists pilocarpine and
[2-ethyl-8-methyl-2,8-diazaspiro(4.5)decane-1,3-dione] hydrochloride (RS86) and the cholinesterase inhibitor physostigmine all
decreased the percentage of avoidance responses at doses that produced
less than approximately 30% response failures. Similar results were
obtained with the antipsychotic drugs haloperidol, trifluoperazine,
chlorpromazine, and clozapine. However, the benzodiazepine anxiolytic diazepam did not decrease avoidance responding up to doses
that produced ataxia. On the other hand, oxotremorine and arecoline
decreased avoidance responding only by producing response failures,
whereas aceclidine produced intermediate changes. The muscarinic
receptor antagonists scopolamine, trihexyphenidyl, and benztropine were
without effect when administered alone but antagonized the decreases in
avoidance responding produced by pilocarpine and RS86. Scopolamine had
little effect on the decreases in avoidance responding produced by
haloperidol. The newer muscarinic receptor partial agonists or
agonist/antagonists
[R-(Z)-(+)-
-(methoxyimino)-1-azabicyclo[2.2.2]octane-3-acetonitrile] hydrochloride, talsaclidine, milameline, and xanomeline also produced dose-related decreases in avoidance responding. Our results demonstrate that muscarinic receptor agonists can decrease avoidance responding in
a manner similar to dopamine-receptor antipsychotic drugs, suggesting
that muscarinic receptor agonists may provide an alternative approach
to the treatment of psychosis.
This article has been cited by other articles:
![]() |
A. Shekhar, W. Z. Potter, J. Lightfoot, J. Lienemann, S. Dube, C. Mallinckrodt, F. P. Bymaster, D. L. McKinzie, and C. C. Felder Selective Muscarinic Receptor Agonist Xanomeline as a Novel Treatment Approach for Schizophrenia Am J Psychiatry, August 1, 2008; 165(8): 1033 - 1039. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Breier Developing Drugs for Cognitive Impairment in Schizophrenia Schizophr Bull, October 1, 2005; 31(4): 816 - 822. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. K. Jones, E. L. Eberle, D. B. Shaw, D. L. McKinzie, and H. E. Shannon Pharmacologic Interactions between the Muscarinic Cholinergic and Dopaminergic Systems in the Modulation of Prepulse Inhibition in Rats J. Pharmacol. Exp. Ther., March 1, 2005; 312(3): 1055 - 1063. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Sarter, C. L Nelson, and J. P Bruno Cortical Cholinergic Transmission and Cortical Information Processing in Schizophrenia Schizophr Bull, January 1, 2005; 31(1): 117 - 138. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. J. Raedler, M. B. Knable, D. W. Jones, R. A. Urbina, J. G. Gorey, K. S. Lee, M. F. Egan, R. Coppola, and D. R. Weinberger In Vivo Determination of Muscarinic Acetylcholine Receptor Availability in Schizophrenia Am J Psychiatry, January 1, 2003; 160(1): 118 - 127. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. J. Stanhope, N. R. Mirza, M. J. Bickerdike, J. L. Bright, N. R. Harrington, M. B. Hesselink, G. A. Kennett, S. Lightowler, M. J. Sheardown, R. Syed, et al. The Muscarinic Receptor Agonist Xanomeline Has an Antipsychotic-Like Profile in the Rat J. Pharmacol. Exp. Ther., November 1, 2001; 299(2): 782 - 792. [Abstract] [Full Text] [PDF] |
||||